KR101987559B1 - A cosmetic composition having excellent skin moisturizing effect - Google Patents
A cosmetic composition having excellent skin moisturizing effect Download PDFInfo
- Publication number
- KR101987559B1 KR101987559B1 KR1020170169299A KR20170169299A KR101987559B1 KR 101987559 B1 KR101987559 B1 KR 101987559B1 KR 1020170169299 A KR1020170169299 A KR 1020170169299A KR 20170169299 A KR20170169299 A KR 20170169299A KR 101987559 B1 KR101987559 B1 KR 101987559B1
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic composition
- hyaluronic acid
- skin
- water
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 239000002537 cosmetic Substances 0.000 title claims abstract description 41
- 230000003020 moisturizing effect Effects 0.000 title abstract description 19
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 44
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 44
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 44
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 21
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 21
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 21
- -1 glyceryl glucoside Chemical class 0.000 claims abstract description 18
- 229930182478 glucoside Natural products 0.000 claims abstract description 12
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 11
- 229920006037 cross link polymer Polymers 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims 1
- 229940014041 hyaluronate Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 46
- 230000000052 comparative effect Effects 0.000 description 15
- 210000004207 dermis Anatomy 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 7
- 239000003921 oil Substances 0.000 description 6
- 230000036572 transepidermal water loss Effects 0.000 description 6
- 102000010637 Aquaporins Human genes 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 108010063290 Aquaporins Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000007903 penetration ability Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940043810 zinc pyrithione Drugs 0.000 description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- FHYNZKLNCPUNEU-UHFFFAOYSA-N 4-[(3,4-dihydroxyphenyl)methyl]-3-[(4-hydroxyphenyl)methyl]oxolan-2-one Chemical compound C1=CC(O)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(O)=C1 FHYNZKLNCPUNEU-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- ZWXYEWJNBYQXLK-UHFFFAOYSA-N azanium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [NH4+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O ZWXYEWJNBYQXLK-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940070721 polyacrylate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 피부 보습 효과가 우수한 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition having excellent skin moisturizing effect.
히알루론산(Hyaluronic acid, HA)은 N-아세틸글루코사민(N-acetyl glucosamine)과 글루코로닉애씨드(Glucoronic acid)가 교대로 결합한 고분자 화합물로서 인체에 존재하는 전체 히알루론산의 50%가 피부에 분포한다. 특히 피부에서 히알루론산의 감소는 노화에 따른 피부의 질적 변화와 관련되어 있다고 제시되어 있으며, 레티노이드의 항노화 효과는 히알루론산에도 영향을 준다고 알려져 있다. 또한 피부과에서 피부결의 개선 혹은 주름을 개선할 목적으로 진피 내에 주사하여 피부의 호전을 유발한다. 히알루론산은 진피뿐 아니라 표피에서도 세포외 기질의 중요한 성분이다.Hyaluronic acid (HA) is a polymer compound in which N-acetyl glucosamine and gluconic acid are alternately bound, and 50% of the total hyaluronic acid present in the human body is distributed in the skin . In particular, the reduction of hyaluronic acid in the skin is suggested to be related to the qualitative change of the skin due to aging, and the anti-aging effect of the retinoid is also known to affect hyaluronic acid. In addition, in the dermatology, the skin is improved by injecting into the dermis for the purpose of improving the skin texture or improving the wrinkles. Hyaluronic acid is an important component of the extracellular matrix in the epidermis as well as in the dermis.
표피에서 히알루론산은 조직 구조를 지지하는 물리적 역할 외에도 표피의 증식과 분화의 조절, 수분의 항상성 유지, 상처 치유 과정 촉진, 표피 투과 장벽의 항상성 유지, 면역 반응 등의 다양한 역할을 수행하여 표피의 항상성에 관여하고 있다.In addition to physical roles supporting tissue structure, hyaluronic acid plays various roles such as control of epidermal proliferation and differentiation, maintenance of water homeostasis, promotion of wound healing, homeostasis of epidermal permeation barrier, and immune response, .
최근에는 히알루론산의 분자량에 따라 표피의 구조와 기능에 미치는 영향이 다르다는 것이 알려져 있다. 25~100kDa의 분자량이 작은 히알루론산은 각질형성세포의 증식과 세포 이동을 촉진시키고, 50~400kDa의 중간 크기 히알루론산을 피부에 도포하면 노화된 피부와 스테로이드 치료에 의한 피부 위축을 방지하거나 표피의 정상 두께를 다시 회복 할 수 있다고 보고되었다. 또한, 600kDa 이상의 고분자량을 갖는 히알루론산은 각질혈성세포의 분화를 조절한다. 또한 고분자 히알루론산은 내피세포의 증식 억제, 저분자 히알루론산은 증식 활성을 통한 혈관생성을 촉진하는 것으로 알려져 있다.Recently, it has been known that the molecular weight of hyaluronic acid has different effects on the structure and function of epidermis. Hyaluronic acid with a molecular weight of 25-100 kDa promotes proliferation and cell migration of keratinocytes and application of medium sized hyaluronic acid of 50-400 kDa to the skin prevents skin atrophy caused by aged skin and steroid treatment, It is reported that normal thickness can be restored. In addition, hyaluronic acid having a high molecular weight of 600 kDa or more regulates differentiation of keratinocytes. It is also known that polymer hyaluronic acid promotes endothelial cell proliferation and low molecular weight hyaluronic acid promotes angiogenesis through proliferative activity.
본 발명과 관련한 선행기술로는 대한민국 등록특허공보 제10-1737446호(2017.05.29. 공고, 발명의 명칭: 피부 보습용 화장료 조성물)에 개시되어 있다.A prior art related to the present invention is disclosed in Korean Patent Publication No. 10-1737446 (published on Feb. 27, 201, entitled Cosmetic composition for skin moisturizing).
본 발명의 하나의 목적은 피부 도포시 유효 성분의 경피 침투력이 우수하며, 장시간의 피부 보습이 가능하고, 피부 수분량 유지 효과가 우수한 화장료 조성물을 제공하는 것이다.It is an object of the present invention to provide a cosmetic composition which is excellent in percutaneous penetration power of an active ingredient when applied to the skin, can moisturize the skin for a long time, and has an excellent skin moisture retaining effect.
본 발명의 다른 목적은 피부 자극이 없고, 인체에 무해한 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition free from skin irritation and harmless to human body.
본 발명의 또 다른 목적은 사용감 및 제형 안정성이 우수한 화장료 조성물을 제공하는 것이다.It is still another object of the present invention to provide a cosmetic composition which is excellent in feeling and stability in formulation.
본 발명의 하나의 관점은 피부 보습 효과가 우수한 화장료 조성물에 관한 것이다. 한 구체예에서 상기 화장료 조성물은 하이드롤라이즈드 글라이코사미노글리칸(hydrolyzed glycosaminoglycan), 글리세릴글루코사이드(glyceryl glucoside) 및 히알루론산(hyaluronic acid) 혼합물을 유효성분으로 포함하며, 상기 히알루론산 혼합물은 분자량 2~10kDa의 하이알루로닉애씨드(hyaluronic acid), 분자량 50~3,000kDa의 소듐하이알루로네이트(sodium Hyaluronate) 및 분자량 3,000kDa 초과인 소듐하이알루로네이트크로스폴리머(Sodium hyaluronate crosspolymer)를 포함한다.One aspect of the present invention relates to a cosmetic composition having excellent skin moisturizing effect. In one embodiment, the cosmetic composition comprises a mixture of hydrolyzed glycosaminoglycan, glyceryl glucoside, and hyaluronic acid as an active ingredient, wherein the hyaluronic acid mixture comprises A hyaluronic acid having a molecular weight of 2 to 10 kDa, sodium hyaluronate having a molecular weight of 50 to 3,000 kDa and a sodium hyaluronate crosspolymer having a molecular weight of 3,000 kDa or more do.
한 구체예에서 상기 하이드롤라이즈드 글라이코사미노글리칸, 글리세릴글루코사이드 및 히알루론산 혼합물은 1:1~3:0.1~8 중량비로 포함될 수 있다.In one embodiment, the hydrolyzed glycosaminoglycan, glyceryl glucoside, and hyaluronic acid mixture may be included in a weight ratio of 1: 1 to 3: 0.1 to 8.
한 구체예에서 상기 히알루론산 혼합물은 하이알루로닉애씨드, 소듐하이알루로네이트 및 소듐하이알루로네이트크로스폴리머를 1:0.1~5:1~15 중량비로 포함할 수 있다.In one embodiment, the hyaluronic acid mixture may comprise hyaluronic acid, sodium hyaluronate, and sodium hyaluronate crosspolymer in a weight ratio of 1: 0.1-5: 1-15.
한 구체예에서 상기 화장료 조성물 전체중량에 대하여 하이드롤라이즈드 글라이코사미노글리칸 0.1~5 중량%, 글리세릴글루코사이드 0.1~8 중량% 및 히알루론산 혼합물 0.001~30 중량% 포함될 수 있다.In one embodiment, 0.1 to 5 wt% of hydrolized glycosaminoglycan, 0.1 to 8 wt% of glyceryl glucoside, and 0.001 to 30 wt% of a hyaluronic acid mixture may be included relative to the total weight of the cosmetic composition.
한 구체예에서 상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 또는 스프레이 제형을 가질 수 있다.In one embodiment, the cosmetic composition may be a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, have.
한 구체예에서 상기 화장료 조성물은 Oil-in-Water(수중유형)(O/W), Water-in-Oil(유중수형)(W/O), Water-in-Silicone(실리콘중수형)(W/S), Oil-in-Water-in-Oil(유중수중유형)(O/W/O) 또는 Water-in-Oil-in-Water(수중유중수형)(W/O/W) 제형일 수 있다.In one embodiment, the cosmetic composition comprises at least one of an oil-in-water (O / W), a water-in-oil (W / O), a water-in- / S), Oil-in-Water-in-Oil (O / W / O) or Water-in-Oil-in-Water (W / O / W) .
본 발명의 화장료 조성물은 피부 도포시 유효 성분의 경피 침투력이 우수하며, 피부 표면에 수분 필름막 형성을 통하여, 장시간 피부 수분 함유량, 진피 보습 지속력 및 경표피수분손실(Transepidermal Water loss, TEWL) 감소력 효과가 우수하며, 피부 자극이 없고, 인체에 무해하며, 사용감 및 제형 안정성이 우수할 수 있다.The cosmetic composition of the present invention is excellent in transdermal penetration ability of an active ingredient when applied to skin and has a long-term skin moisture content, dermal moisturizing persistence and transepidermal water loss (TEWL) reduction effect And is free of skin irritation, harmless to human body, and can be excellent in feeling and stability of formulation.
도 1은 본 발명에 따른 실시예 및 본 발명에 대한 비교예 화장료 조성물을 피험자들의 피부에 도포하고 시간 경과에 따른 피부의 수분함유량의 변화를 나타낸 그래프이다.
도 2는 본 발명에 따른 실시예 및 본 발명에 대한 비교예 화장료 조성물을 피험자들의 피부에 도포하고 시간 경과에 따른 피부 진피 수분함유량의 변화를 나타낸 그래프이다.
도 3은 본 발명에 따른 실시예 및 본 발명에 대한 비교예 화장료 조성물을 피험자들의 피부에 도포하고 시간 경과에 따른 경표피수분손실량의 변화를 나타낸 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing changes in the moisture content of the skin over time according to the examples of the present invention and the comparative cosmetic composition of the present invention applied to the skin of the subjects. FIG.
FIG. 2 is a graph showing changes in moisture content of skin dermis over time, by applying the examples according to the present invention and the comparative cosmetic composition according to the present invention to the skin of the subjects.
FIG. 3 is a graph showing changes in the amount of water-loss of light-skinned skin according to the present invention and the time course of application of the cosmetic composition of the present invention to the skin of a subject.
본 발명을 설명함에 있어서 관련된 공지기술 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명은 생략할 것이다.In the following description of the present invention, a detailed description of known functions and configurations incorporated herein will be omitted when it may make the subject matter of the present invention rather unclear.
그리고 후술되는 용어들은 본 발명에서의 기능을 고려하여 정의된 용어들로써 이는 사용자, 운용자의 의도 또는 관례 등에 따라 달라질 수 있으므로 그 정의는 본 발명을 설명하는 본 명세서 전반에 걸친 내용을 토대로 내려져야 할 것이다.It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed.
화장료Cosmetics 조성물 Composition
본 발명의 하나의 관점은 피부 보습 효과가 우수한 화장료 조성물에 관한 것이다. 한 구체예에서 상기 화장료 조성물은 하이드롤라이즈드 글라이코사미노글리칸(hydrolyzed glycosaminoglycan), 글리세릴글루코사이드(glyceryl glucoside) 및 히알루론산(hyaluronic acid) 혼합물을 유효성분으로 포함하며, 상기 히알루론산 혼합물은 분자량 2~10kDa의 하이알루로닉애씨드(hyaluronic acid), 분자량 50~3,000kDa의 소듐하이알루로네이트(sodium Hyaluronate) 및 분자량 3,000kDa 초과인 소듐하이알루로네이트크로스폴리머(Sodium hyaluronate crosspolymer)를 포함한다.One aspect of the present invention relates to a cosmetic composition having excellent skin moisturizing effect. In one embodiment, the cosmetic composition comprises a mixture of hydrolyzed glycosaminoglycan, glyceryl glucoside, and hyaluronic acid as an active ingredient, wherein the hyaluronic acid mixture comprises A hyaluronic acid having a molecular weight of 2 to 10 kDa, sodium hyaluronate having a molecular weight of 50 to 3,000 kDa and a sodium hyaluronate crosspolymer having a molecular weight of 3,000 kDa or more do.
상기 하이드롤라이즈드 글라이코사미노글리칸(hydrolyzed glycosaminoglycan)을 포함시, 상기 유효성분의 경피 침투력을 향상시켜 피부 보습효과를 더욱 향상시킨다.When the hydrolyzed glycosaminoglycan is included, the transdermal penetration power of the active ingredient is improved to further improve the skin moisturizing effect.
한 구체예에서 상기 하이드롤라이즈드 글라이코사미노글리칸은 상기 화장료 조성물 전체중량에 대하여 0.1~5 중량% 포함될 수 있다. 상기 범위로 포함시, 제형 안정성이 저하되지 않으면서 보습 효과가 우수할 수 있다. 예를 들면 0.1~3 중량% 포함될 수 있다.In one embodiment, the hydrolized glycosaminoglycan may be included in an amount of 0.1 to 5% by weight based on the total weight of the cosmetic composition. When included in the above range, the formulation stability may not be deteriorated and the moisturizing effect may be excellent. For example, 0.1 to 3% by weight.
상기 글리세릴글루코사이드(glyceryl glucoside)는, 수분 채널인 Aquaporins(AQPs)의 활성화와 관련된 물질로, 현재 알려진 13개 AQPs 중 표피에 있는 탁월한 수분 채널인 AQP3를 활성화하는 성분으로 알려져 있다. 상기 글리세릴글루코사이드를 포함시, 수분 보습력을 더욱 향상시킬 수 있다. 또한 분자량이 낮아 피부 세포벽을 쉽게 통과할 수 있으며, 사용감이 우수하여 피부 적용시 끈적임 없이 가볍고 산뜻한 느낌을 준다. 또한, 냉동보존력과 안전성이 우수하여, 자체 방부력이 우수하며, 피부 친화성이 우수할 수 있다.Glyceryl glucoside is a substance related to the activation of Aquaporins (AQPs), which is a water channel, and is known to activate AQP3, an excellent water channel in the epidermis among 13 known AQPs. When the glyceryl glucoside is contained, the moisture-retaining ability can be further improved. In addition, it has low molecular weight and can easily pass through the cell wall of skin. It has excellent feel and gives a feeling of lightness and freshness without stickiness when applied to skin. In addition, it has excellent freezing preservation ability and safety, has excellent self-repellency, and is excellent in skin-affinity.
한 구체예에서 상기 글리세릴글루코사이드는 상기 화장료 조성물 전체중량에 대하여 0.1~8 중량% 포함될 수 있다. 상기 범위로 포함시, 제형 안정성이 저하되지 않으면서, 사용감 및 보습 효과가 우수할 수 있다. 예를 들면 0.1~5 중량% 포함될 수 있다.In one embodiment, the glyceryl glucoside may be included in an amount of 0.1 to 8% by weight based on the total weight of the cosmetic composition. Within the above range, the feeling of use and the moisturizing effect can be excellent without lowering the formulation stability. For example, 0.1 to 5% by weight.
상기 히알루론산(hyaluronic acid) 혼합물은, 콜라겐 및 엘라스틴 등과 함께, 피부 구성 요소 중 하나로 작용한다. 또한 히알루론산은 피부 내 진피의 주요 구성 성분으로 수분 보유 능력이 우수하여 수분 유지, 세포간 간격 유지 역할 뿐만 아니라, 세포의 성장, 분열 및 이동 등에 관여하는 것으로 알려져 있다.The hyaluronic acid mixture, together with collagen and elastin, acts as one of the skin components. In addition, hyaluronic acid is a major constituent of the dermis in the skin and is known to be involved in growth, division, and migration of cells as well as maintaining water retention and intercellular spacing as well as water retention ability.
본 발명의 히알루론산 혼합물은 분자량 2~10kDa의 하이알루로닉애씨드(hyaluronic acid), 분자량 50~3,000kDa의 소듐하이알루로네이트(sodium Hyaluronate) 및 분자량 3,000kDa 초과인 소듐하이알루로네이트크로스폴리머(Sodium hyaluronate crosspolymer)를 포함한다.The hyaluronic acid mixture of the present invention comprises hyaluronic acid having a molecular weight of 2 to 10 kDa, sodium hyaluronate having a molecular weight of 50 to 3,000 kDa and a sodium hyaluronate crosspolymer having a molecular weight of more than 3,000 kDa (Sodium hyaluronate crosspolymer).
상기 분자량 2~10kDa의 하이알루로닉애씨드는 하기 화학식 1과 같은 구조를 포함할 수 있다. The hyaluronic acid having a molecular weight of 2 to 10 kDa may have a structure represented by the following formula (1).
[화학식 1][Chemical Formula 1]
상기 분자량을 갖는 하이알루로닉애씨드는 피부 내에서 보습 및 히알루론산 합성 촉진효과를 가질 수 있다.The hyaluronic acid having the above molecular weight may have moisturizing and hyaluronic acid synthesis promoting effect in the skin.
상기 분자량 50~3,000kDa의 소듐하이알루로네이트 및 상기 분자량 3,000kDa 초과인 소듐하이알루로네이트크로스폴리머는 하기 화학식 2와 같은 구조를 포함할 수 있다.The sodium hyaluronate having a molecular weight of 50 to 3,000 kDa and the sodium hyaluronate cross polymer having a molecular weight of more than 3,000 kDa may have a structure as shown in the following Chemical Formula 2.
[화학식 2](2)
상기 분자량 50~3,000kDa의 소듐하이알루로네이트는 피부 내에서 보습 및 히알루론산 합성 촉진효과를 가질 수 있다.The sodium hyaluronate having a molecular weight of 50 to 3,000 kDa may have moisturizing and hyaluronic acid synthesis promoting effect in the skin.
상기 분자량 3,000kDa 초과인 소듐하이알루로네이트크로스폴리머는 피부 표면에 수분 필름막을 형성시킬 수 있다. 예를 들면, 상기 소듐하이알루로네이트크로스폴리머의 분자량은 3,000kDa 초과 100,000kDa일 수 있다.The sodium hyaluronate crosspolymer having a molecular weight of more than 3,000 kDa can form a moisture film on the skin surface. For example, the molecular weight of the sodium hyaluronate crosspolymer may be greater than 3,000 kDa and 100,000 kDa.
한 구체예에서 상기 히알루론산 혼합물은 상기 화장료 조성물 전체중량에 대하여 0.001~30 중량% 포함될 수 있다. 상기 범위로 포함시, 제형 안정성이 저하되지 않으면서, 끈적임을 최소화할 수 있어 사용감이 우수하고, 피부에 도포시 장시간 피부 수분 함유량, 진피 보습 지속력 및 경표피수분손실(Transepidermal Water loss, TEWL) 감소력 효과가 우수할 수 있다. 예를 들면 0.05~20 중량% 포함될 수 있다. 다른 예를 들면 0.1~10 중량% 포함될 수 있다.In one embodiment, the hyaluronic acid mixture may be included in an amount of 0.001 to 30% by weight based on the total weight of the cosmetic composition. When included in the above range, it is possible to minimize tackiness without deteriorating formulation stability, and is excellent in feeling of use. Further, when applied to the skin, the skin moisture content, dermal moisture retention and transepidermal water loss (TEWL) The power effect can be excellent. For example, 0.05 to 20% by weight. For example, 0.1 to 10% by weight.
한 구체예에서 상기 히알루론산 혼합물은 하이알루로닉애씨드, 소듐하이알루로네이트 및 소듐하이알루로네이트크로스폴리머를 1:0.1~5:1~15 중량비로 포함할 수 있다. 상기 중량비로 포함시, 상기 화장료 조성물의 제형 안정성이 우수하면서, 끈적임을 최소화할 수 있어 사용감이 우수하고, 히알루론산 혼합물 성분 사이에 예측할 수 없는 상승효과가 발생하여, 피부 수분함유량, 피부 진피 수분 함유량을 장시간 유지시키고, 경표피수분손실량을 감소시킬 수 있다. 예를 들면 1:0.5~3:2~10의 중량비로 포함할 수 있다.In one embodiment, the hyaluronic acid mixture may comprise hyaluronic acid, sodium hyaluronate, and sodium hyaluronate crosspolymer in a weight ratio of 1: 0.1-5: 1-15. When included in the above weight ratio, the formulation stability of the cosmetic composition is excellent, tackiness can be minimized, the feeling of use is excellent, an unpredictable synergistic effect occurs between hyaluronic acid mixture components, and skin moisture content, Can be maintained for a long time, and the amount of water-loss of the hard skin can be reduced. For example, in a weight ratio of 1: 0.5 to 3: 2 to 10.
한 구체예에서 상기 하이드롤라이즈드 글라이코사미노글리칸, 글리세릴글루코사이드 및 히알루론산 혼합물은 1:0.5~3:0.1~8 중량비로 포함될 수 있다. 상기 중량비로 포함시, 피부 자극성이 없으면서, 상기 화장료 조성물의 제형 안정성이 우수하고, 끈적임을 최소화할 수 있어 사용감이 우수하며, 본 발명의 상기한 유효 성분 사이에 예측할 수 없는 상승효과가 발생하여 피부 수분함유량, 피부 진피 수분 함유량을 장시간 유지시키고, 경표피수분손실량을 감소시킬 수 있다. 예를 들면, 1:0.5~1.5:0.2~6 중량비로 포함될 수 있다.In one embodiment, the hydrolyzed glycosaminoglycan, glyceryl glucoside, and hyaluronic acid mixture may be included in a weight ratio of 1: 0.5 to 3: 0.1 to 8. When the cosmetic composition of the present invention is contained in the above weight ratio, the cosmetic composition of the present invention is excellent in formulation stability, minimizes tackiness, and is excellent in feeling of use and has an unpredictable synergistic effect between the above- The water content and the skin dermis moisture content can be maintained for a long time, and the amount of water-loss of the epidermis can be reduced. For example, in a weight ratio of 1: 0.5 to 1.5: 0.2 to 6.
한 구체예에서 상기 화장료 조성물은 통상적인 화장료 조성물에 배합될 수 있는 성분을 더 포함할 수 있다. 예를 들면 물, 용해보조제, 계면활성제, 보습제, 점증제, pH 조정제, 방부제, 산화방지제, 금속이온봉쇄제, 살균제, 항염증제, 항미생물제, 가용화제 또는 착향제, 염료, 안료 등을 더 포함할 수 있다.In one embodiment, the cosmetic composition may further comprise ingredients that can be formulated into conventional cosmetic compositions. It may further comprise water, a solubilizer, a surfactant, a moisturizer, an agitator, a pH adjuster, a preservative, an antioxidant, a sequestering agent, a bactericide, an anti-inflammatory agent, an antimicrobial agent, a solubilizing agent or a flavoring agent, .
본 발명에 따른 화장료 조성물에 포함될 수 있는 계면활성제는 암모늄라우릴술포석시네이트, 암모늄라우릴설페이트 등과 같은 음이온계 계면활성제와 폴리옥시에틸렌알킬에테르, 폴리옥시에틸렌지방산에스테르 등과 같은 비이온성 계면활성제 등이 가능하다. 또한, 3급 지방족 아민염, 알킬트리메칠암모늄클로라이드 등과 같은 양이온성 계면활성제와 베타인, 아미드베타인형과 같은 양쪽성 계면활성제 등이 될 수 있다.Surfactants that can be included in the cosmetic composition according to the present invention include anionic surfactants such as ammonium laurylsulfosuccinate and ammonium lauryl sulfate and nonionic surfactants such as polyoxyethylene alkyl ether and polyoxyethylene fatty acid ester This is possible. Also, cationic surfactants such as tertiary aliphatic amine salts, alkyltrimethylammonium chloride and the like and amphoteric surfactants such as betaine, amide betaine and the like can be used.
상기 보습제는 소듐하이알루로네이트, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 디프로필렌글리콜, 소르비톨 등이 될 수 있으며, 점증제는 폴리아크릴레이트, 잔탄검, 메틸셀룰로스, 하이드록시에틸셀룰로스, 카라기난, 카르복시메틸셀룰로스, 하이드록시메틸셀룰로스 등의 화합물이 될 수 있다. 또한, pH 조정제는 구체적으로 구연산, 수산화나트륨, 트리에탄올아민, 구연산나트륨, 인산, 인산나트륨, 젖산 등이 가능하다.The moisturizing agent may be sodium hyaluronate, glycerin, propylene glycol, 1,3-butylene glycol, dipropylene glycol, sorbitol, etc. The thickener may be polyacrylate, xanthan gum, methyl cellulose, hydroxyethyl cellulose , Carrageenan, carboxymethylcellulose, hydroxymethylcellulose, and the like. The pH adjuster may specifically include citric acid, sodium hydroxide, triethanolamine, sodium citrate, phosphoric acid, sodium phosphate, lactic acid, and the like.
상기 방부제는 벤조산, 파라옥시안식향산에스테르, 메칠클로로이소치아졸리논의 혼합물, 페녹시에탄올, 디엠디엠히단토인 등이 될 수 있으며, 산화방지제는 구체적으로 디부틸히드록시톨루엔, 아스코르빈산 등이 가능하다.The preservative may be benzoic acid, paraoxybenzoic acid ester, a mixture of methylchloroisothiazolinone, phenoxyethanol, DMDM, and the like. Specific examples of the antioxidant include dibutylhydroxytoluene and ascorbic acid .
상기 금속이온봉쇄제는 에칠렌디아민테트라초산디나트륨, 에칠렌디아민테트라초산테트라나트륨 등이 가능하며, 살균제는 구체적으로 클로르헥시딘 글루코네이트, 4급 암모늄염, 피록톤올아민, 아연피리치온 현탁액, 요도프로피닐 부틸카바메이트, 살리실산 등이 될 수 있다.The metal ion sequestering agent may be disodium ethylenediaminetetraacetate, tetranodium ethylenediaminetetraacetate, and the like. Specifically, the disinfectant may be chlorhexidine gluconate, quaternary ammonium salt, pyrrothonol amine, zinc pyrithione suspension, urethropropylbutyl Carbamate, salicylic acid, and the like.
상기 항염증성분으로는 글리시리진산모노암모늄, 글리시리진산디칼륨, 알란토인 및 이들의 혼합물 등이 가능하며, 항균(항미생물)성분은 구체적으로 페녹시에탄올, 클로르헥시딘, 클로르헥시딘 글루코네이트, 벤조산 및 그의 염, 벤질알코올, 살리실산, 트리클로카르반, 아연피리치온 현탁액 및 그들의 혼합물 등을 사용할 수 있다.Examples of the anti-inflammatory component include monoammonium glycyrrhizinate, dipotassium glycyrrhizinate, allantoin, and mixtures thereof. The antibacterial (antimicrobial) component specifically includes phenoxyethanol, chlorhexidine, chlorhexidine gluconate, benzoic acid and its salts, benzyl Alcohols, salicylic acid, trichlorocarbane, zinc pyrithione suspensions, and mixtures thereof.
상기 가용화제로는 구체적으로 피이지 60-하이드로제네이티드 캐스터오일 등이 될 수 있으며, 상기 착향제는 본 발명의 화장료 조성물 분야에 사용되는 통상의 성분을 사용할 수 있다.The solubilizing agent may specifically be a phage 60-hydrogenated castor oil or the like, and the flavoring agent may be a conventional ingredient used in the cosmetic composition field of the present invention.
한 구체예에서 상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 젤, 크림, 로션, 파우더, 비누, 클린징, 오일, 파운데이션, 왁스 또는 스프레이 제형일 수 있다. 예를 들면, 앰플, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이, 파우더, 팩트, 립글로즈, 립스틱, 섀도우, 샴푸 및 린스 등의 제형으로 제조될 수 있다.In one embodiment, the cosmetic composition may be a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, cleansing oil, foundation, wax or spray formulation. For example, Ampoules, Flexible lotion, Nourishing lotion, Nourishing cream, Massage cream, Essence, Eye cream, Cleansing cream, Cleansing foam, Cleansing water, Pack, Spray, Powder, Fact, Lip gloss, Lipstick, Shadow, Shampoo and Conditioner And the like.
한 구체예에서 상기 화장료 조성물은 Oil-in-Water(수중유형)(O/W), Water-in-Oil(유중수형)(W/O), Water-in-Silicone(실리콘중수형)(W/S), Oil-in-Water-in-Oil(유중수중유형)(O/W/O) 또는 Water-in-Oil-in-Water(수중유중수형)(W/O/W) 제형일 수 있다.In one embodiment, the cosmetic composition comprises at least one of an oil-in-water (O / W), a water-in-oil (W / O), a water-in- / S), Oil-in-Water-in-Oil (O / W / O) or Water-in-Oil-in-Water (W / O / W) .
본 발명의 화장료 조성물은 피부 도포시 유효 성분의 경피 침투력이 우수하며, 피부 표면에 수분 필름막 형성을 통하여, 장시간 피부 수분 함유량, 진피 보습 지속력 및 경표피수분손실(Transepidermal Water loss, TEWL) 감소력 효과가 우수하며, 피부 자극이 없고, 인체에 무해하며, 사용감 및 제형 안정성이 우수할 수 있다.The cosmetic composition of the present invention is excellent in transdermal penetration ability of an active ingredient when applied to skin and has a long-term skin moisture content, dermal moisturizing persistence and transepidermal water loss (TEWL) reduction effect And is free of skin irritation, harmless to human body, and can be excellent in feeling and stability of formulation.
이하, 본 발명의 바람직한 실시예를 통해 본 발명의 구성 및 작용을 더욱 상세히 설명하기로 한다. 다만, 이는 본 발명의 바람직한 예시로 제시된 것이며 어떠한 의미로도 이에 의해 본 발명이 제한되는 것으로 해석될 수는 없다.Hereinafter, the configuration and operation of the present invention will be described in more detail with reference to preferred embodiments of the present invention. It is to be understood, however, that the same is by way of illustration and example only and is not to be construed in a limiting sense.
실시예Example 및 And 비교예Comparative Example
실시예Example 1~3 및 1 to 3 and 비교예Comparative Example 1~5 1-5
하기 표 1에 따른 성분 및 함량을 적용하여, 크림 형태의 제형을 갖는 화장료 조성물을 제조하였다.The components and the contents according to the following Table 1 were applied to prepare cosmetic compositions having cream formulations.
실험예Experimental Example 1. One. 사용감에On feeling 대한 비교 실험 Comparative experiment for
상기 실시예 1~3 및 비교예 1~5 화장료 조성물에 대하여, 끈적임, 종합적인 사용감 및 보습력을 측정하여 그 결과를 하기 표 2에 나타내었다. 사용감 측정은 건강한 피부를 가진 20명의 대상자를 통하여 얻었으며, 각 항목의 속성이 ‘전혀없다’는 ‘-’로, ‘아주 많다’는 ‘+++’로 표시하였다. 그 사이의 값을 ‘+(조금 느껴진다)’와 ‘++(어느 정도 느껴진다)’로 표시하도록 하였다.For the cosmetic compositions of Examples 1 to 3 and Comparative Examples 1 to 5, stickiness, comprehensive feeling of use and moisturizing power were measured, and the results are shown in Table 2 below. The sensory evaluation was obtained through 20 subjects with healthy skin. The attributes of each item were '-' for 'no' and '+++' for 'very many'. The values between them are indicated as '+ (feel a little)' and '++ (feel somewhat)'.
상기 표 2를 참조하면 실시예 1~3은 끈적임이 적고, 보습감이 우수하여 사용감이 우수한 것으로 나타났다. 반면, 본 발명의 히알루론산 혼합물 구성 성분을 단독으로 적용한 비교예 1~3의 경우, 보습감이 저하되거나 끈적임이 발생하는 것을 알 수 있었다. 또한, 본 발명의 하이드롤라이즈드 글라이코사미노글리칸 및 글리세릴글루코사이드를 각각 포함하지 않는 비교예 4 및 5의 경우 끈적임, 보습감 또는 사용감이 저하됨을 알 수 있었다.Referring to Table 2, Examples 1 to 3 showed less tackiness and excellent moisturizing feeling and excellent feeling of use. On the other hand, in the case of Comparative Examples 1 to 3 in which the hyaluronic acid mixture component of the present invention was solely applied, it was found that the moisturizing feel was reduced or the stickiness was generated. It was also found that Comparative Examples 4 and 5, which did not contain the hydrolized glycosaminoglycan and glyceryl glucoside, respectively, of the present invention were reduced in stickiness, moisturizing feeling, or feeling of use.
실험예Experimental Example 2. 시간 경과에 따른 피부 수분 함유량 2. Skin moisture content over time
상기 실시예 및 비교예 중에서, 대표적으로 실시예 2 및 비교예 3에 대하여 시간 경과(사용전, 사용직후, 4시간 후, 24시간 후)에 따른 피부 수분 함유량을 측정하여 그 결과를 하기 도 1에 나타내었다. 상기 피부 수분 함유량 시험은 만 19~59세의 성인 여성 20명을 대상으로 실시하였다. 측정은 피부 수분 함유량을 측정하는 Corneometer 825를 사용하여 항온항습조건(온도 20~24℃, 습도 40~60%)의 공간에서 약 30분간 피부 안정을 취해 측정 환경에 적응하도록 하였고, 매번 같은 조건에서 측정하였다. 측정된 피부 수분함유량의 단위는 A.U(Arbitrary Unit)이며 측정값과 피부 보습값은 비례한다.The skin moisture content according to the time course (before use, immediately after use, after 4 hours, and after 24 hours) of the Example 2 and the Comparative Example 3 was measured, and the results are shown in Fig. 1 Respectively. The skin moisture content test was conducted on 20 adult women aged 19 to 59 years. The measurement was performed by using a Corneometer 825, which measures the skin moisture content, in order to adapt to the measurement environment by taking the skin stability for about 30 minutes in a space of constant temperature and humidity (
상기 도 1의 결과를 참조하면, 피부 수분함유량의 경우 실시예 2가 무도포군, 비교예 3보다 높은 것을 알 수 있었다.Referring to the results of FIG. 1, it can be seen that the skin moisture content of Example 2 is higher than that of the non-treated skin and Comparative Example 3.
실험예Experimental Example 3. 시간 경과에 따른 피부 수분 함유량 3. Skin moisture content over time
상기 실시예 2 및 비교예 3에 대하여, 상기 실험예 2와 동일한 대상자들에 대하여, 항온항습조건(온도 20~24℃, 습도 40~60%)에서, Moisturemeter D compact를 사용하여 시간 경과에 따른 피부 진피 수분 함유량을 측정하여 그 결과를 하기 도 2에 나타내었다. 측정된 진피 수분 함유량의 단위는 %이며, 측정값과 진피 수분 함유량은 비례한다.With respect to Example 2 and Comparative Example 3, the same subjects as in Experimental Example 2 were subjected to constant temperature and humidity conditions (
상기 도 2를 참조하면, 진피 수분 함유량의 경우 실시예 2가 무도포군, 비교예 3보다 높은 것을 알 수 있었다.Referring to FIG. 2, it can be seen that the dermal moisture content of Example 2 is higher than that of the non-dermal preparation and Comparative Example 3.
실험예Experimental Example 4. 시간 경과에 따른 4. Over time 경표피수분손실량Light skin moisture loss 측정 Measure
상기 실시예 2 및 비교예 3에 대하여, 상기 실험예 2와 동일한 대상자들에 대하여, 항온항습조건(온도 20~24℃, 습도 40~60%)에서 Vapometer을 사용하여 시간 경과에 따른 경표피수분손실량을 측정하여 그 결과를 하기 도 3에 나타내었다. 측정된 경표피수분손실량의 단위는 g/m2h이다. 측정값과 경표피수분손실량은 비례하므로 측정값이 낮아질수록 경표피수분손실량이 적어 피부 표피층의 수분 손실이 감소함을 나타낸다.With respect to Example 2 and Comparative Example 3, the same subjects as in Experimental Example 2 were subjected to constant temperature and humidity conditions (
상기 도 3을 참조하면, 경표피수분손실량의 경우 실시예 2가 무도포군, 비교예 3보다 경표피수분손실 감소력이 우수한 것을 알 수 있었다.Referring to FIG. 3, it was found that the water-loss of the hard-skin layer was superior to that of the non-water-soluble group of Example 2 and that of the water-loss of the hard-skin layer.
실험예Experimental Example 5: 제형 안정성 평가 5: Formulation stability evaluation
실시예 1~3 및 비교예 1~5에 대하여 50℃, 40℃, 25℃ 및 5℃의 온도에서 각각 4주 동안 보관 후 분리 및 변색 정도를 비교 측정하고, 그 결과를 하기 표 3에 나타내었다. 이때 제품의 분리 및 변색 정도는 하기의 6 등급으로 분류하여 평가하였다.The separation and discoloration degree of each of Examples 1 to 3 and Comparative Examples 1 to 5 were measured after storage at 50 ° C, 40 ° C, 25 ° C and 5 ° C for 4 weeks, respectively, and the results are shown in Table 3 . The degree of separation and discoloration of the product was classified into the following six grades and evaluated.
* 분리 및 변색 평가 기준* Separation and discoloration evaluation criteria
0: 변화 없음, 1: 극히 조금 분리(변색), 2: 조금 분리(변색), 3: 조금 심하게 분리(변색), 4: 심하게 분리(변색), 5: 극히 심하게 분리(변색)4: Severely separated (discolored), 5: Severely separated (discolored), 2: slightly separated (discolored), 3: slightly separated (discolored)
상기 표 3을 참조하면, 상기 실시예 1~3의 경우, 화장료 조성물의 제형 안정성이 우수하였으며, 비교예 1~5의 경우, 상기 실시예 1~3 보다 제형의 점도가 증가하거나, 제형의 분리가 발생하는 등 제형안정성이 저하되었음을 알 수 있었다.The results are shown in Table 3. Referring to Table 3, the formulation stability of the cosmetic composition was excellent in Examples 1 to 3, and in Comparative Examples 1 to 5, the viscosity of the formulation increased, The stability of the formulation was deteriorated.
본 발명의 단순한 변형 내지 변경은 이 분야의 통상의 지식을 가진 자에 의하여 용이하게 실시될 수 있으며, 이러한 변형이나 변경은 모두 본 발명의 영역에 포함되는 것으로 볼 수 있다.It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (6)
상기 히알루론산 혼합물은 분자량 2~10kDa의 하이알루로닉애씨드(hyaluronic acid), 분자량 50~3,000kDa의 소듐하이알루로네이트(sodium Hyaluronate) 및 분자량 3,000kDa 초과인 소듐하이알루로네이트크로스폴리머(Sodium hyaluronate crosspolymer)를 1:0.5~3:2~10 중량비로 포함하는 것을 특징으로 하는 화장료 조성물.
0.1 to 5% by weight of hydrolyzed glycosaminoglycan, 0.1 to 8% by weight of glyceryl glucoside and 0.001 to 30% by weight of a mixture of hyaluronic acid as an active ingredient In addition,
The hyaluronic acid mixture may contain hyaluronic acid having a molecular weight of 2 to 10 kDa, sodium hyaluronate having a molecular weight of 50 to 3,000 kDa and sodium hyaluronate having a molecular weight of 3,000 kDa or more hyaluronate crosspolymer) in a ratio of 1: 0.5 to 3: 2 to 10 by weight.
The cosmetic composition according to claim 1, wherein the hydrolyzed glycosaminoglycan, glyceryl glucoside, and hyaluronic acid mixture are contained in a weight ratio of 1: 1 to 3: 0.1 to 8.
The cosmetic composition according to claim 1, wherein the cosmetic composition is in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, Or a pharmaceutically acceptable salt thereof.
The cosmetic composition according to claim 1, wherein the cosmetic composition is at least one selected from the group consisting of Oil-in-Water (O / W), Water-in-Oil (W / O), Water-in- (W / O), Water-in-Water-in-Oil (W / O) Wherein the composition is a formulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170169299A KR101987559B1 (en) | 2017-12-11 | 2017-12-11 | A cosmetic composition having excellent skin moisturizing effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170169299A KR101987559B1 (en) | 2017-12-11 | 2017-12-11 | A cosmetic composition having excellent skin moisturizing effect |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101987559B1 true KR101987559B1 (en) | 2019-06-10 |
Family
ID=66848594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170169299A Active KR101987559B1 (en) | 2017-12-11 | 2017-12-11 | A cosmetic composition having excellent skin moisturizing effect |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101987559B1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102049698B1 (en) * | 2019-06-28 | 2020-01-22 | 주식회사 신세계인터코스코리아 | Cosmetic composition for improving skin conditions |
US11110117B2 (en) | 2019-07-17 | 2021-09-07 | J2Kbio Co., Ltd. | Skin preparation composition for external use containing complex hyaluronic acid |
KR20220144537A (en) * | 2021-04-20 | 2022-10-27 | 한순생 | Skin moisturizing cosmetic composition |
KR102472483B1 (en) * | 2022-01-14 | 2022-12-01 | 주식회사 한국화장품제조 | Cosmetic composition having exfoliating effect and moisturizing effect |
KR20230005012A (en) * | 2021-06-30 | 2023-01-09 | 주식회사 고운세상코스메틱 | A cosmetic composition having excellent skin hydration density improvement effect |
KR102549636B1 (en) * | 2022-10-05 | 2023-06-30 | 주식회사 셀템제약 | Cosmetic composition for enhancing skin absorption of EGF |
CN117599080A (en) * | 2023-12-13 | 2024-02-27 | 北京中研创科医疗科技有限公司 | Pharmaceutical composition containing hyaluronic acid or salt thereof and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090068219A1 (en) * | 2007-09-10 | 2009-03-12 | 3Lab, Inc. | Anti-wrinkle hormone-type cosmetic composition |
US20120308621A1 (en) * | 2009-12-11 | 2012-12-06 | Novejarque Conde Jose Antonio | Base formulation for cosmetic products |
US20130089579A1 (en) * | 2011-10-11 | 2013-04-11 | Biopolymer Gmbh & Co. Kg | Combination of Hyaluronic Acid and Prilocaine |
US20160220475A1 (en) * | 2013-08-29 | 2016-08-04 | Beiersdorf Ag | Emulsifier-free, skin conditioning and active ingredient-containing cosmetic or dermatological preparation |
US9693947B1 (en) * | 2017-02-03 | 2017-07-04 | Jan Marini Skin Research | HYLA3D hylauronic acid activating complex |
-
2017
- 2017-12-11 KR KR1020170169299A patent/KR101987559B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090068219A1 (en) * | 2007-09-10 | 2009-03-12 | 3Lab, Inc. | Anti-wrinkle hormone-type cosmetic composition |
US20120308621A1 (en) * | 2009-12-11 | 2012-12-06 | Novejarque Conde Jose Antonio | Base formulation for cosmetic products |
US20130089579A1 (en) * | 2011-10-11 | 2013-04-11 | Biopolymer Gmbh & Co. Kg | Combination of Hyaluronic Acid and Prilocaine |
US20160220475A1 (en) * | 2013-08-29 | 2016-08-04 | Beiersdorf Ag | Emulsifier-free, skin conditioning and active ingredient-containing cosmetic or dermatological preparation |
US9693947B1 (en) * | 2017-02-03 | 2017-07-04 | Jan Marini Skin Research | HYLA3D hylauronic acid activating complex |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102049698B1 (en) * | 2019-06-28 | 2020-01-22 | 주식회사 신세계인터코스코리아 | Cosmetic composition for improving skin conditions |
US11110117B2 (en) | 2019-07-17 | 2021-09-07 | J2Kbio Co., Ltd. | Skin preparation composition for external use containing complex hyaluronic acid |
KR20220144537A (en) * | 2021-04-20 | 2022-10-27 | 한순생 | Skin moisturizing cosmetic composition |
KR102562120B1 (en) * | 2021-04-20 | 2023-07-31 | 한순생 | Skin moisturizing cosmetic composition |
KR20230005012A (en) * | 2021-06-30 | 2023-01-09 | 주식회사 고운세상코스메틱 | A cosmetic composition having excellent skin hydration density improvement effect |
KR102580067B1 (en) | 2021-06-30 | 2023-09-22 | 주식회사 고운세상코스메틱 | A cosmetic composition having excellent skin hydration density improvement effect |
KR102472483B1 (en) * | 2022-01-14 | 2022-12-01 | 주식회사 한국화장품제조 | Cosmetic composition having exfoliating effect and moisturizing effect |
KR102549636B1 (en) * | 2022-10-05 | 2023-06-30 | 주식회사 셀템제약 | Cosmetic composition for enhancing skin absorption of EGF |
CN117599080A (en) * | 2023-12-13 | 2024-02-27 | 北京中研创科医疗科技有限公司 | Pharmaceutical composition containing hyaluronic acid or salt thereof and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101987559B1 (en) | A cosmetic composition having excellent skin moisturizing effect | |
JP7307835B2 (en) | aqueous composition | |
KR102043485B1 (en) | Oil-in-water emulsion composition | |
JPS6323166B2 (en) | ||
JP2011513267A (en) | Combinations of active ingredients and their use | |
KR20140015109A (en) | Antibacterial composition, composition for prevention or treatment of periodontal diseases, and preservative for cosmetics | |
KR20180109329A (en) | Cosmetic composition containing moisturizing complex | |
JP2019077675A (en) | Gel-like external preparation for skin and skin cosmetic | |
EP2322138A2 (en) | Antimicrobial composition | |
EP3769750A1 (en) | A hyaluronic acid composition for external use on skin and its use | |
KR102412958B1 (en) | Antibacterial or conservative composition containing polyglycerine-3 | |
KR20110013000A (en) | Moisturizing cosmetic composition having an effect of relieving dryness and itching by removing dead skin cells and increasing moisture content | |
JP2021054721A (en) | Method for improving stickiness of adenosine-phosphate-containing composition | |
JP5455292B2 (en) | Skin external composition | |
KR102040490B1 (en) | A cosmetic composition having excellent skin cooling with skin moisturizing effect | |
CA2972238C (en) | Personal care composition with zinc phosphate active | |
US20110002861A1 (en) | Composition comprising pure aloe and its use as a cosmetic base | |
JP2013216637A (en) | Skin external preparation | |
JP3479048B2 (en) | Cosmetics and non-woven fabric impregnated cosmetics | |
JPH09291013A (en) | Skin cosmetic material | |
US20230149274A1 (en) | An antimicrobial composition for tackling malodour | |
JP2022547420A (en) | Silicone-free, low-friction cleanser with high foaming properties | |
JP7541759B2 (en) | Antibacterial skin preparations | |
JP4246150B2 (en) | Skin cosmetic composition | |
JPH07215832A (en) | Skin external preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20171211 |
|
PA0201 | Request for examination | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190118 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20190524 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20190603 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20190603 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20220325 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20240320 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20250324 Start annual number: 7 End annual number: 7 |